Brainstorm Cell Therapeutics Inc
NASDAQ:BCLI
Net Margin
Brainstorm Cell Therapeutics Inc
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
Country | US |
Market Cap | 34.2m USD |
Net Margin | N/A |
Country | US |
Market Cap | 288.5B USD |
Net Margin |
9%
|
Country | US |
Market Cap | 171.3B USD |
Net Margin |
13%
|
Country | US |
Market Cap | 112.8B USD |
Net Margin |
37%
|
Country | US |
Market Cap | 107.5B USD |
Net Margin |
29%
|
Country | AU |
Market Cap | 136.7B AUD |
Net Margin |
17%
|
Country | US |
Market Cap | 84.4B USD |
Net Margin |
2%
|
Country | US |
Market Cap | 49B USD |
Net Margin |
-116%
|
Country | US |
Market Cap | 43.1B USD |
Net Margin |
-33%
|
Country | US |
Market Cap | 34.3B USD |
Net Margin |
12%
|
Country | KR |
Market Cap | 39.6T KRW |
Net Margin |
25%
|
Profitability Report
View the profitability report to see the full profitability analysis for Brainstorm Cell Therapeutics Inc.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Brainstorm Cell Therapeutics Inc's most recent financial statements, the company has Net Margin of 0%.